Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypyrimidine tract-binding protein 1 (PTBP1) is a modular RNA-binding protein composed of four RNA recognition motifs (RRMs), structurally classified as a heterogeneous nuclear ribonucleoprotein (hnRNP)[7][4][3]. PTBP1 binds preferentially to polypyrimidine tracts in pre-mRNA introns, where it regulates multiple steps of RNA maturation, including alternative splicing, polyadenylation, mRNA localization, stability, and translation (notably internal ribosome entry site, IRES-mediated translation)[6][4][7][1]. In the nucleus, PTBP1 acts primarily as a splicing repressor by binding to polypyrimidine-rich sequences near splice junctions[7][6], but can both repress and activate splicing in a context-dependent manner by modulating exon definition[2]. PTBP1 additionally serves as an RNA chaperone, remodeling secondary RNA structures to control translation initiation and the fate of specific mRNAs[2][1]. Beyond splicing, it modulates microRNA function and acts as a key regulator of neuronal development—suppression of PTBP1 expression by miR-124 promotes neuronal differentiation[2]. In cancer, overexpression of PTBP1 drives aberrant splicing patterns that favor tumor progression, metabolic reprogramming (such as promoting the PKM2 isoform), and chemoresistance; it is thus studied as a biomarker and potential cancer therapeutic target[2]. PTBP1’s dysregulation is also implicated in viral infection (by facilitating cap-independent translation of viral RNA)[1] and potentially in neurodegenerative disease[2]. PTBP1's interaction with cellular proteins, such as the prosurvival protein MCL1, reveals an additional regulatory axis through which its splicing and translational effects may be modulated[4]. No small-molecule drugs directly targeting PTBP1 are currently approved; its broad role in RNA processing presents both opportunities and challenges for safe therapeutic targeting due to its potential widespread effects on gene expression[2][4].
Modulate alternative splicing; Inhibit/enhance translation via RNA structural modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polypyrimidine tract-binding protein 1 (PTBP1).